NCT06504368

Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors

An Open-Label, Phase 1, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous DCR-PDL1 in Adults With Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study will evaluate the safety, tolerability, and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors. Participants will be enrolled in one of 4 ascending-dose cohorts. Each treatment cycle will consist of multiple intravenous (IV) doses. Dose escalation decisions will be based on data collected during the dose-limiting toxicity (DLT) period.

Conditions

• Solid Tumors, Adult

Interventions

Type	Name	Description
DRUG	DCR-PDL1	Solution for IV Infusion

Timeline

• Start date: 2024-05-29
• Primary completion: 2026-06-01
• Completion: 2027-12-31
• First posted: 2024-07-16
• Last updated: 2025-11-06

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study